Education
About Us
Working with TipRanks
Follow Us
Somnomed Limited (AU:SOM)
ASX:SOM
SOM Stock Chart & Stats
AU$0.72
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.72
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$154.00M
Enterprise ValueAU$137.09M
Total Cash (Recent Filing)AU$17.29M
Total Debt (Recent Filing)AU$8.03M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Feb 27, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding218,443,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSomnomed's double-digit revenue growth reflects rising adoption of its oral appliance therapy and expanding clinician reach. Durable top-line momentum supports scale economics, strengthens negotiating leverage with suppliers and channels, and underpins medium-term investment in product and market expansion.
Strong Cash GenerationA >562% improvement in free cash flow and positive operating cash flow despite net losses indicates robust cash conversion from operations. That durable cash generation provides runway for R&D, international rollouts and working capital, reducing reliance on external financing over the next several quarters.
Conservative Capital StructureLow leverage (D/E ~0.17) and a stable equity base give Somnomed financial flexibility and lower default risk. This conservative capital structure supports investment in growth initiatives and buffers the business against reimbursement or demand volatility without materially increasing financial stress.
Bears Say
Persistent UnprofitabilityDespite revenue gains, Somnomed remains unprofitable at the EBIT and net levels. Persistent negative margins limit the company's ability to internally fund expansion or return capital, increasing sensitivity to revenue dips and requiring sustained margin improvement to achieve durable shareholder returns.
Operating Cost PressureA healthy ~60% gross margin alongside negative EBIT implies elevated SG&A, sales or R&D spending relative to revenue. If operating cost structure is not tightened or offset by faster revenue scale, profitability will remain elusive, constraining long-term free cash flow conversion and return on invested capital.
Revenue Reliance On Clinician/Reimbursement DynamicsSomnomed's clinician-led distribution and dependence on referrals and reimbursement create structural demand risk. Changes in referral patterns, payer coverage or dentist adoption rates can durably affect device uptake and revenue predictability over the next several quarters, complicating growth visibility.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.37 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$154.00M.
When is Somnomed Limited’s upcoming earnings report date?
Somnomed Limited’s upcoming earnings report date is Feb 27, 2026 which is in 4 days.
How were Somnomed Limited’s earnings last quarter?
Somnomed Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.002 by -AU$0.005.
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Overvalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate is 0.3.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 218,443,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Somnomed Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.002. Following the earnings report the stock price went up 0.633%.
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-7.26%
Trailing 12-Months
Asset Growth
13.83%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---